NCT04630015: Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients receiving primary cancer treatment outside of University of California, San Francisco (UCSF)

Comments are closed.

Up ↑